Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single site, randomized, double-blind Phase III clinical trial to
evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of
triple-negative breast cancer patients.